Ignite Creation Date:
2024-05-06 @ 2:16 PM
Last Modification Date:
2024-10-26 @ 1:28 PM
Study NCT ID:
NCT04265534
Status:
TERMINATED
Last Update Posted:
2022-09-21
First Post:
2020-02-07
Brief Title:
KEAPSAKE A Study of Telaglenastat CB-839 With Standard-of-Care Chemoimmunotherapy in 1L KEAP1NRF2-Mutated Nonsquamous NSCLC
Sponsor:
Calithera Biosciences Inc
Organization:
Calithera Biosciences Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-07-24
Start Date Type:
ACTUAL
Primary Completion Date:
2021-11-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-02-09
Completion Date Type:
ACTUAL
First Submit Date:
2020-02-07
First Submit QC Date:
February 10 2020
Study First Post Date:
2020-02-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
2022-09-15
Disp First Submit QC Date:
September 15 2022
Disp First Post Date:
2022-09-21
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2022-09-15
Last Update Post Date:
2022-09-21
Last Update Post Date Type:
ACTUAL